Data were presented from advancing dosage accretion studies of FG-2216 in bloodless patients with abiding branch ache (CKD).
Previously appear after-effects authenticate that patients not ahead advised with recombinant erythropoietin (EPO) analysis on boilerplate display decidedly added levels of claret (Hb) in acknowledgment to the low dosage of FG-2216 (6 mg/kg) administered orally three times a anniversary for four weeks.
Aboriginal after-effects from the 10 mg/kg dosage accumulation authenticate a beggarly access of 2.7 g/dL Hb in patients dosed alert a anniversary for four weeks.As allotment of advancing efforts to actuate optimal dosing, the abstraction agreement was revised to abate dosing akin and frequency.
more about: FG-2216
from: Pharmaceutical Ingredients
No comments:
Post a Comment